FRANKLIN, Tenn., April 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report first quarter 2024 financial results after market close on Tuesday, May 7, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on May 7, 2024, to discuss the Company’s business and financial results.
First Quarter 2024 Conference Call and Webcast Details:
About Clover Health
Clover Health (Nasdaq: CLOV) is a physician enablement company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease.
Press Contact:
Andrew Still-Baxter
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Ryan Schmidt
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$4.18 |
Daily Change: | 0.05 1.21 |
Daily Volume: | 16,963,218 |
Market Cap: | US$1.700B |
September 03, 2024 August 22, 2024 August 05, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB